Trovagene (TROV) Misses Q2 EPS by 17c

Trovagene (NASDAQ: TROV) reported Q2 EPS of ($0.41), $0.17 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $50 thousand versus the consensus estimate of $30 thousand.

"Our pilot commercial team has gained impressive traction in the field, delivering stronger than expected participation by oncologists in our Clinical Experience Program," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "Additionally, we continue to demonstrate in clinical studies the utility of our Precision Cancer Monitoring platform to detect and monitor validated driver mutations in several cancer types. Our goals over the next several quarters are clear and include increasing the number of oncologists using our assays in clinical practice, presenting and publishing additional clinical study results supporting the utility of our tests, and expanding the mutation coverage of our platform. Liquid biopsy for cancer monitoring offers tremendous potential, and our recently competed capital raise strengthens our balance sheet and positions us to execute on our business plan, improve the care of cancer patients, and increase shareholder value."

For earnings history and earnings-related data on Trovagene (TROV) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• BeyondSpring Inc. (BYSI) Reports Q2 Loss of $0.02
• Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform